What type of study is this?

September 5, 2025Open Access

Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper

Ask AI

Bookmark

CAR T cell therapy effectively controls myeloma even when BCMA expression is limited, indicating resilience.
Key evidence includes observation of antigen expression on different target cell lines demonstrating variability.
The approach involves an analysis of immune responses against distinct target cell lines expressing BCMA and CD229 antigens.
Implications of these findings suggest potential for broader application in cases with limited BCMA expression.

Observational analysis shows CAR T cell efficacy in myeloma, highlighting antigen expression complexity.

BCMA and CD229 antigen expression on different target cell lines used in different experiments.

No takes yet. Share an insight, caveat, or question.

Rodríguez‐Lobato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows CAR T cell efficacy in myeloma, highlighting antigen expression complexity.

BCMA and CD229 antigen expression on different target cell lines used in different experiments.